Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
MedCap AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was 2.84%.
The industry rank for MedCap AB's 3-Year RORE % or its related term are showing as below:
OSTO:MCAP's 3-Year RORE % is ranked better than 57.4% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.07
vs OSTO:MCAP: 2.84
MedCap AB (OSTO:MCAP) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
MedCap AB 3-Year RORE % Related Terms
MedCap AB 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for MedCap AB's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: 3-Year RORE % Comparison
For the Medical Devices subindustry, MedCap AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where MedCap AB's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
MedCap AB (OSTO:MCAP) has a 3-Year RORE % of 2.84 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MedCap AB and its competitors. According to the industry distribution chart, MedCap AB ranks #331 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 42.6%.
Is MedCap AB's 3-Year RORE % too high?
MedCap AB's current 3-Year RORE % is 2.84. Based on the distribution chart, MedCap AB ranks #331 out of 777 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MedCap AB has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's 3-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #331 out of 777 companies for 3-Year RORE %. This puts MedCap AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on MedCap AB and its competitors. MedCap AB's current 3-Year RORE % is 2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr556.75, compared to a current price of kr519.50 — trading 6.7% below its estimated fair value. The current 3-Year RORE % is 2.84. MedCap AB's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current 3-Year RORE % is 2.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr519.50 is trading 6.7% below its estimated GF Value™ of kr556.75.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
3-Year RORE %: 2.84
GF Value™: kr556.75 vs. price of kr519.50 (6.7% below fair value)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
80GF Score
Get the complete analysis for OSTO:MCAP
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
